CoChat
Sign Up
Cited by 141Psychedelics and Drug StudiesParanormal Experiences and BeliefsReligion, Spirituality, and Psychology

The DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index, and 1 are not checked yet.

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience

Open access
Peill, Joseph M, Trinci, Katie E, Kettner, Hannes, Mertens, Lea J, Roseman, Leor, Timmermann, Christopher, Rosas, Fernando E, Lyons, Taylor, Carhart-Harris, Robin L·2022·Journal of Psychopharmacology
DOI 10.1177/02698811211066709PMC PMC8801624
Open this paper in CoChat — free account

Abstract

Introduction: As their name suggests, ‘psychedelic’ (mind-revealing) compounds are thought to catalyse processes of psychological insight; however, few satisfactory scales exist to sample this. This study sought to develop a new scale to measure psychological insight after a psychedelic experience: the Psychological Insight Scale (PIS). Methods: The PIS is a six- to seven-item questionnaire that enquires about psychological insight after a psychedelic experience (PIS-6) and accompanied behavioural changes (PIS item 7). In total, 886 participants took part in a study in which the PIS and other questionnaires were completed in a prospective fashion in relation to a planned psychedelic experience. For validation purposes, data from 279 participants were analysed from a non-specific ‘global psychedelic survey’ study. Results: Principal components analysis of PIS scores revealed a principal component explaining 73.57% of the variance, which displayed high internal consistency at multiple timepoints throughout the study (average Cronbach’s α = 0.94). Criterion validity was confirmed using the global psychedelic survey study, and convergent validity was confirmed via the Therapeutic-Realizations Scale. Furthermore, PIS scores significantly mediated the relationship between emotional breakthrough and long-term well-being. Conclusion: The PIS is complementary to current subjective measures used in psychedelic studies, most of which are completed in relation to the acute experience. Insight – as measured by the PIS – was found to be a key mediator of long-term psychological outcomes following a psychedelic experience. Future research may investigate how insight varies throughout a psychedelic process, its underlying neurobiology and how it impacts behaviour and mental health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/02698811211066709

Cites

95 of 96 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. In a causal path analysis model, psychological well-being 2 weeks after a psychedelic experience is significantly predicted by the acute psychedelic state (CEQ, EBI, MEQ), while controlling for baseline well-being (not shown). Mystical and challenging experiences directly affect well-being, whereas the effect of emotional breakthrough experiences was mediated through psychological insight. Only paths and standardised coefficients significant below p = 0.05 are displayed. *p < 0.05, **p < 0.01, ***p < 0.001. CEQ: Challenging Experience Questionnaire; EBI: Emotional Breakthrough Inventory; MEQ: Mystical Experience Questionnaire.
Figure 1. In a causal path analysis model, psychological well-being 2 weeks after a psychedelic experience is significantly predicted by the acute psychedelic state (CEQ, EBI, MEQ), while controlling for baseline well-being (not shown). Mystical and challenging experiences directly affect well-being, whereas the effect of emotional breakthrough experiences was mediated through psychological insight. Only paths and standardised coefficients significant below p = 0.05 are displayed. *p < 0.05, **p < 0.01, ***p < 0.001. CEQ: Challenging Experience Questionnaire; EBI: Emotional Breakthrough Inventory; MEQ: Mystical Experience Questionnaire.CC BY · PubMed Central
Figure 2. Correlation analysis between well-being scores (WEMWBS) at 2 weeks post-retreat and psychological insight (as measured using the PIS) at 1-day post-retreat. Participants with low baseline WEMWBS (⩽43) demonstrated the strongest correlation (rs = 0.506, n = 120), followed by all participants (rs = 0.344, n = 312). Displayed are the Spearman’s correlation coefficients (rs). WEMWBS: Warwick–Edinburgh Mental Well-Being Scale; PIS: Psychological Insight Scale. ***p < 0.001.
Figure 2. Correlation analysis between well-being scores (WEMWBS) at 2 weeks post-retreat and psychological insight (as measured using the PIS) at 1-day post-retreat. Participants with low baseline WEMWBS (⩽43) demonstrated the strongest correlation (rs = 0.506, n = 120), followed by all participants (rs = 0.344, n = 312). Displayed are the Spearman’s correlation coefficients (rs). WEMWBS: Warwick–Edinburgh Mental Well-Being Scale; PIS: Psychological Insight Scale. ***p < 0.001.CC BY · PubMed Central
Figure 3. Predictive validity in study 2: Correlation analyses of psychological insight (PIS-6) measured 1-day post-psychedelic experience with changes in well-being (as measured by the WEMWBS) after 2 weeks (ΔWEMWBS2 weeks) within the total sample (n = 190) and low well-being subgroup (baseline WEMWBS score ⩽43, n = 69). Displayed are the Spearman’s correlation coefficients (rs). WEMWBS: Warwick–Edinburgh Mental Well-Being Scale. ***p < 0.001.
Figure 3. Predictive validity in study 2: Correlation analyses of psychological insight (PIS-6) measured 1-day post-psychedelic experience with changes in well-being (as measured by the WEMWBS) after 2 weeks (ΔWEMWBS2 weeks) within the total sample (n = 190) and low well-being subgroup (baseline WEMWBS score ⩽43, n = 69). Displayed are the Spearman’s correlation coefficients (rs). WEMWBS: Warwick–Edinburgh Mental Well-Being Scale. ***p < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Research works printed but not linked: 7

  1. Acock AC, 2014, A Gentle Introduction to Stata
  2. Dittrich A, 2010, 5D-ASC: Questionnaire for the assessment of altered states of consciousness – A short introduction
  3. Fisher FM, 2015, Therapy with Substance: Psycholytic Psychotherapy in the Twenty First Century
  4. Greenberg L, 1987, The Guilford Clinical Psychology and Psychotherapy Series – Emotion in Psychotherapy: Affect, Cognition, and the Process of Change
  5. Grof S, 1980, LSD Psychotherapy
  6. Pahnke WN, 1963, Drugs and Mysticism: An Analysis of the Relationship between Psychedelic Drugs and the Mystical Consciousness: A Thesis
  7. Savage C, 1966, International Journal of Neuropsychiatry, 2, 241

Cited by

Sorted by citations

See all 141

Related

Metadata

Authors
Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L.
Affiliations
  • Imperial College London (GB)
  • University College London (GB)
  • University of California, San Francisco (US)
Corresponding author
Trinci, Katie E
ORCID
Venue
Journal of Psychopharmacology
Publisher
SAGE Publications
Published
2022-01
Volume
36
Issue
1
Pages
31-45
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
DOI
10.1177/02698811211066709
PMC
PMC8801624
OpenAlex
W4206700491
Cited by
141
References
96
Citations by year
2026: 23 · 2025: 22 · 2024: 36 · 2023: 47 · 2022: 13
FWCI
26.94
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
  • Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords
psychological insight, psychedelic experience, scale validation, long-term well-being, subjective outcome measures
MeSH terms
Adult, Aged, Awareness, Female, Hallucinogens, Humans, Male, Middle Aged, Prospective Studies, Psychometrics, Surveys and Questionnaires, Principal Component Analysis, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review